siremadlin
Small moleculeexperimental
Clinical trial activity
13 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Jul 7, 2014 (NCT02143635)
Timeline
Indications
Studied for
- Colorectal Neoplasms · Phase 1
- Hematopoietic Stem Cell Transplantation · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Liposarcoma · Phase 1/Phase 2
- Liver Diseases · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 2
- Neuroblastoma · Phase 1
- Primary Myelofibrosis · Phase 1/Phase 2
- Sarcoma · Phase 1/Phase 2
Mechanism of action
- p53-binding protein Mdm-2INHIBITOR
MDM2 inhibitor
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1- Mol. weight
- 555.42 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3653256 ↗
Also known as
- hdm201
- hdm201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05599932 | Phase 1 | Dec 2, 2022 | Novartis |
| NCT05447663 | Phase 1/Phase 2 (Phase 2) | Nov 21, 2022 | Novartis |
| NCT05180695 | Phase 1/Phase 2 (Phase 2) | Apr 15, 2022 | Centre Leon Berard, National Cancer Institute, France, Novartis |
| NCT05155709 | Phase 1/Phase 2 (Phase 2) | Feb 24, 2022 | Novartis |
| NCT04496999 | Phase 1 | Nov 16, 2020 | University of Bern |
| NCT04116541 | Phase 2 | Nov 30, 2019 | Centre Leon Berard |
| NCT04097821 | Phase 1/Phase 2 (Phase 2) | Sep 18, 2019 | Novartis |
| NCT03760445 | Phase 1/Phase 2 (Phase 2) | May 31, 2019 | Novartis |
| NCT03940352 | Phase 1 | May 10, 2019 | Novartis |
| NCT03714958 | Phase 1 | Dec 20, 2018 | Centre Leon Berard, Novartis |
| NCT02780128 | Phase 1 | Jul 1, 2016 | Children's Hospital of Philadelphia, Foundation Medicine, Novartis, University of Pennsylvania |
| NCT02343172 | Phase 1/Phase 2 (Phase 2) | Mar 13, 2015 | Novartis |
| NCT02143635 | Phase 1 | Jul 7, 2014 | Novartis |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 11 | 8 | 2 | 2014 |
| Centre Leon Berard | Academic/Hospital | 3 | 3 | 2 | 2018 |
| Children's Hospital of Philadelphia | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Foundation Medicine | For profit | 1 | 0 | 1 | 2016 |
| National Cancer Institute, France | Government | 1 | 0 | 1 | 2022 |
| University of Bern | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2016 |
7 organizations
Page 1 / 1